Patents by Inventor Hirofumi Omura

Hirofumi Omura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220112233
    Abstract: Provided are a method for producing a peptide compound including a step of using a condensed polycyclic aromatic hydrocarbon compound represented by Formula (1); a protective group-forming reagent including the compound; and the compound. In Formula (1), a ring A represents a condensed polycyclic aromatic hydrocarbon ring, YA's each independently represent —OH, —NHR, —SH, or —X0, where X0 represents Cl, Br, or I, RA and RC each independently represent an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group, RBs' each independently represent a monovalent aliphatic hydrocarbon group, a (1+c)-valent aromatic group, or a (1+c)-valent heteroaromatic group, where, in a case where both a and c is 0, RB is a monovalent aliphatic hydrocarbon group, and the number of carbon atoms in at least one aliphatic hydrocarbon group is 12 or more.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Yosuke YAMAMOTO, Kazuhei KANEKO, Hirofumi OMURA, Motomasa TAKAHASHI, Makoto TAKAHASHI
  • Patent number: 11208421
    Abstract: An object of the present invention is to provide a compound and a pharmaceutical composition which exhibit strong antibacterial activity against Gram-negative bacteria and drug-resistant Gram-negative bacteria. According to the present invention, a compound represented by General Formula [1] (the reference signs in the formula have the same definitions as those described in the present specification) or a salt thereof has strong antibacterial activity against Gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa, and the pharmaceutical composition containing the compound or a salt thereof is useful as an antibacterial agent.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: December 28, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Muneo Shoji, Kentaro Furuya, Kei Matsuura, Hiromi Hayashi, Tetsuya Matsushita, Hirofumi Omura
  • Publication number: 20210380634
    Abstract: Provided are a method for producing a peptide compound including a step of using a condensed polycyclic aromatic hydrocarbon compound represented by Formula (1); a protective group-forming reagent including the compound; and the compound. In Formula (1), a ring A represents a condensed polycyclic aromatic hydrocarbon ring, YA's each independently represent —CH2OH, —CH2NHR, —CH2SH, or —CH2X0, where R represents a hydrogen atom, an alkyl group, or an aralkyl group, and X0 represents Cl, Br, or I, k represents an integer of 1 to 5, n represents 1 or 2, and RA's each independently represent an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group.
    Type: Application
    Filed: August 22, 2021
    Publication date: December 9, 2021
    Inventors: Yosuke YAMAMOTO, Kazuhei KANEKO, Motomasa TAKAHASHI, Makoto TAKAHASHI, Mika IMAMURA, Hirotaka SATOU, Hirofumi OMURA, Yuji YOSHIMITSU, Daisuke NAKAGAWA, Keita TANAKA
  • Publication number: 20210380633
    Abstract: Provided are a method for producing a peptide compound including a step of using an aromatic heterocyclic compound represented by Formula (1) represented by Formula (1); a protective group-forming reagent including the compound; and the compound. In Formula (1), a ring A represents an aromatic heterocyclic ring, YA's each independently represent —OH, —NHR, —SH, or —X0, where X0 represents Cl, Br, or I, RA and RC each independently represent an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group, RBs' each independently represent a monovalent aliphatic hydrocarbon group, a (1+c)-valent aromatic group, or a (1+c)-valent heteroaromatic group, where, in a case where both a and c is 0, RB is a monovalent aliphatic hydrocarbon group, and the number of carbon atoms in at least one aliphatic hydrocarbon group of RA, RB, or RC is 12 or more.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 9, 2021
    Inventors: Yosuke YAMAMOTO, Kazuhei KANEKO, Motomasa TAKAHASHI, Makoto TAKAHASHI, Mika IMAMURA, Hirotaka SATOU, Hirofumi OMURA, Yuji YOSHIMITSU, Keita TANAKA, Daisuke NAKAGAWA
  • Publication number: 20210063825
    Abstract: An object of the invention is to provide a photo-alignment copolymer which makes it possible to produce a photo-alignment film having excellent solvent resistance and liquid crystal aligning properties, and a photo-alignment film and an optical laminate produced using the photo-alignment copolymer. A photo-alignment copolymer of the invention is a photo-alignment copolymer having a repeating unit A including a photo-alignment group represented by Formula (A) and a repeating unit B including a crosslinkable group represented by Formula (B).
    Type: Application
    Filed: November 8, 2020
    Publication date: March 4, 2021
    Applicant: FUJIFILM Corporation
    Inventors: Yutaka NOZOE, Takashi IIZUMI, Kazushige NAKAGAWA, Takahiro KATO, Miho ASAHI, Hirofumi OMURA, Yuki HIRAI
  • Publication number: 20200239495
    Abstract: An object of the present invention is to provide a compound and a pharmaceutical composition which exhibit strong antibacterial activity against Gram-negative bacteria and drug-resistant Gram-negative bacteria. According to the present invention, a compound represented by General Formula [1] (the reference signs in the formula have the same definitions as those described in the present specification) or a salt thereof has strong antibacterial activity against Gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa, and the pharmaceutical composition containing the compound or a salt thereof is useful as an antibacterial agent.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 30, 2020
    Applicant: FUJIFILM Corporation
    Inventors: Muneo SHOJI, Kentaro FURUYA, Kei MATSUURA, Hiromi HAYASHI, Tetsuya MATSUSHITA, Hirofumi OMURA
  • Patent number: 8138177
    Abstract: This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: March 20, 2012
    Assignee: Pfizer Inc.
    Inventors: Kazuo Ando, Makoto Kawai, Tsutomu Masuda, Hirofumi Omura
  • Publication number: 20110230467
    Abstract: [Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.
    Type: Application
    Filed: November 20, 2009
    Publication date: September 22, 2011
    Applicant: Astellas Pharma Inc.
    Inventors: Shohei Shirakami, Fumie Takahashi, Yutaka Nakajima, Hirofumi Omura, Naohiro Aoyama, Hiroshi Sasaki, Takeshi Hondo, Hiroaki Tominaga
  • Publication number: 20090298811
    Abstract: This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein.
    Type: Application
    Filed: September 3, 2007
    Publication date: December 3, 2009
    Inventors: Kazuo Ando, Ingrid Price Buchler, Shridhar Gajanan Hedge, Makoto Kawai, Tsutomu Masuda, Hirofumi Omura
  • Publication number: 20090181957
    Abstract: This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma
    Type: Application
    Filed: March 2, 2006
    Publication date: July 16, 2009
    Inventors: Kazuo Ando, Makoto Kawai, Tsutomu Masuda, Hirofumi Omura
  • Patent number: 5190826
    Abstract: An interlayer for use in sound-insulating laminated glasses which is in the form of a laminated film of two kinds of resin films (A) and (B), each comprising a polyvinyl acetal acetalized with an aldehyde having 6 to 10 carbon atoms for the film (A) or with an aldehyde having 1 to 4 carbon atoms for the film (B), or is in the form of a resin film (C) comprising a mixture of the two kinds of polyvinyl acetal resins. The interlayer mitigates the coincidence effect to prevent the reduction of TL value without impairing the basic characteristics required of laminated glasses thereby permitting the interlayer to exhibit outstanding sound-insulating properties over a wide temperature range for a prolonged period of time.
    Type: Grant
    Filed: May 13, 1991
    Date of Patent: March 2, 1993
    Assignee: Sekisui Chemical Co., Ltd.
    Inventors: Kenichi Asahina, Naoki Ueda, Hirofumi Omura
  • Patent number: 4925725
    Abstract: An interlayer for a laminated glass, said interlayer being composed of a film or sheet of a thermoplastic resin, at least one surface of the film or sheet of a thermoplastic resin having numerous coarse raised and depressed portions and numerous fine raised and depressed portions existing on the surfaces of the coarse raised and depressed portions, the average distance between two adjacent coarse depressed or raised portions being about 2 to about 10 times the 10-point average roughness of the coarse raised and depressed portions measured in accordance with ISO-R468.
    Type: Grant
    Filed: January 4, 1989
    Date of Patent: May 15, 1990
    Assignee: Sekisui Kagaku Kogyo Kabushiki Kaisha
    Inventors: Gen Endo, Hiroyuki Tateishi, Yoshihiro Kawata, Isao Karasudani, Hirofumi Omura